Resources
The following content is intended for healthcare professionals in countries where REBRAIN’s products are used.
News
Rebrain x Worldwide Dystonia Research Center
Partnership aims to develop next-generation data-driven models for personalized deep brain stimulation (DBS) targeting, expanding clinical applications from Parkinson’s disease and essential tremor to dystonia and severe pediatric dystonia with global scalability...
Rebrain unveils its identity: a strong vision for the future of assisted neurosurgery
At Rebrain, innovation has never been an end in itself. It has always been a means to improve the precision of neurosurgical procedures and to have a concrete impact on patients’ lives. Today, we are reaching a new stage of our development with the official launch of...
RebrAin 2025/2026: Expanding Reach, Driving Innovation
Transatlantic expansion RebrAIn’s focus for 2026 is expanding our reach to major neurosurgery reference centers in the US and Europe. Today, our top partner centers by volume are Duke University, University of Virginia (UVA), Pamplona and UCLA. These collaborations...
Rebrain publishes OPTIVIM trial results in Neurosurgery
An innovative and automated method RebrAIn’s service is based on a machine learning model trained on data from successfully treated patients. Using only a standard 3D T1 MRI, the algorithm automatically computes the stereotactic coordinates of the optimal DBS target,...
RebrAIn Achieves MDR Certification for OptimMRI, Expanding Access to Precision Neurosurgery Across Europe
Already FDA 510(k) cleared in 2024, OptimMRI is an AI-powered surgical planning platform that supports Deep Brain Stimulation (DBS) and lesioning procedures (HIFU & Radiosurgery) targeting the STN and VIM regions. With MDR certification now secured, RebrAIn is...
RebrAIn joins the Charter for the Responsible Development of Neurotechnologies
RebrAIn is proud to announce its commitment to the Charter for the Responsible Development of Neurotechnologies, a collective initiative led by public and private stakeholders and supported by the French National Consultative Ethics (CCNE). This initiative is part of...
User’s manual
Information notice
All revisions of the instructions manual are available for download in the list opposite, in English and other languages. This manual details how to retreive and use the marked MRIs for surgery planning. Marked MRIs (3D DICOM) contain the targets as predicted by OptimDBS, a standalone tool developed by Rebrain.
The use of those marked MRIs processed by OptimDBS is restricted to clinicians planning neurosurgery for patients with either Parkinson’s disease or essential tremor, by targeting the subthalamic nucleus (STN) or the ventral intermediate nucleus of the thalamus (VIM).
Carefully reading this instructions manual before use is strongly advised.
Any type of inappropriate use is prohibited.
A hard copy of this instructions manual can be obtained within 5 working days with no extra charge by contacting Rebrain at the following email address: support@rebrain.eu.
Rebrain provides its partners with an access to its secure medical data exchange platform at transfer.rebrain.eu. Please contact our team with the above email address or via this website’s contact form to request an account. The current version of the instructions manual is also available for download on the data exchange platform, through the help menu of a connected account.
The instructions manuals below are available in PDF format. Any standard PDF reader, such as Acrobat Reader or Okular, is necessary
Sont disponibles dans la liste ci-contre toutes les versions du manuel d’utilisation électronique en Français et dans d’autres langues. Ce manuel d’utilisation explique comment récupérer et utiliser lors la planification de la chirurgie les IRM marquées avec des cibles cérébrales prédites par OptimDBS, un logiciel autonome conçu par RebrAIn.
L’utilisation de ces images IRM (3D DICOM) marquées traitées avec OptimDBS est réservée au clinicien prévoyant d’effectuer une intervention neurochirurgicale pour le traitement de patient atteints de la maladie de Parkinson ou de Tremblements Essentiels en ciblant le noyau sous-thalamique, STN, ou le noyau ventral intermédiaire, VIM.
Il est recommandé de lire attentivement ce manuel d’instructions avant utilisation.
Toute utilisation inappropriée est interdite.
Une copie imprimée des instructions d’utilisation peut être obtenue dans les 5 jours ouvrés sans frais supplémentaires en contactant RebrAIn à l’adresse email suivante : support@rebrain.eu.
RebrAIn offre à ses collaborateur un accès à son service sécurisé d’échange de données médicales à transfer.rebrain.eu. Vous pouvez contacter l’équipe via le formulaire de contact pour faire la demande d’un compte. La version courante du manuel d’utilisation électronique est également accessible depuis le menu « Aide » sur la plateforme transfer.rebrain.eu une fois connecté à celle-ci.
Ces instructions d’utilisation sont fournies en format « PDF ». Un logiciel approprié, tel que Adobe Acrobat Reader, est requis pour les lire.
OptimMRI
- CUG_OptimMRIv2_US Rev.2.pdf (Revision #2 | Revision date: 2025-05 | Lang.: English)
- CUG_OptimMRIv2_EN Rev.2.pdf (Revision #2 | Revision date: 2025-05 | Lang.: English)
- CUG_OptimMRIv2_ES Rev.2.pdf (Revision #2 | Revision date: 2025-06 | Lang.: Spanish)
- CUG_OptimMRIv2_FR Rev.1.pdf (Revision #1 | Revision date: 2025-08 | Lang.: French)
OptimDBS
- CUG_OptimDBS-IT-Rev_4.pdf (Revision #4 | Revision date: 2024-06 | Lang.: Italian)
- CUG_OptimDBS-EN-Rev_4.pdf (Revision #4 | Revision date: 2024-06 | Lang.: English)
- CUG_OptimDBS-ES-Rev_4.pdf (Revision #4| Revision date: 2024-06 | Lang.: Spanish)
- CUG_OptimDBS-FR-Rev_4.pdf (Revision #4 | Revision date: 2024-06 | Lang.: French)
List of archived versions
US Clinician User Guides
- CUG_OptimMRIv2_US Rev.2 (Revision #2 | Revision date: 2025-05 | Lang.: English)
EU Clinician User Guides
- CUG_OptimMRIv2_EN Rev.2 (Revision #2 | Revision date: 2025-05 | Lang.: English)
- CUG_OptimMRIv2_ES Rev.2 ‘(Revision #2 | Revision date: 2025-06 | Lang.: Spanish)
- CUG_OptimMRIv2_FR Rev.1 (Revision #1 | Revision date: 2025-08 | Lang.: French)
- CUG_OptimDBS-IT-Rev_3 (Revision #3 | Revision date: 2022-06 | Lang.: Italian)
- CUG_OptimDBS-EN-Rev_3 (Revision #3 | Revision date: 2022-06 | Lang.: English)
- CUG_OptimDBS-ES-Rev_3 (Revision #3 | Revision date: 2022-06 | Lang.: Spanish)
- CUG_OptimDBS-FR-Rev_3 (Revision #3 | Revision date: 2022-06 | Lang.: French)
- CUG_OptimDBS EN Rev.2 (Revision #2 | Revision date: 2021-10 | Lang.: English)
- CUG_OptimDBS FR Rev.2 (Revision #2 | Revision date: 2021-10 | Lang.: French)
- CUG_OptimDBS EN Rev.1 (Revision #1 | Revision date: 2021-04 | Lang.: English)
- CUG_OptimDBS FR Rev.1 (Revision #1 | Revision date: 2021-04 | Lang.: French)
Publications
White Paper
OptimMRI from Rebrain
A personalized, participative, preventive, predictive and evidence-based neurosurgical targeting service for patients with movement disorders caused by Parkinson’s Disease or Essential Tremor.
To receive our complete white paper on OptimMRI, please submit your request via the form below. Your details will help us verify eligibility and ensure the information is sent to the right audience.
